{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:27:04Z","timestamp":1788532024125,"version":"build-2803163510"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cardiovascular disease remains the leading cause of mortality worldwide, with residual cardiovascular (CVS) risk remaining high despite pharmacological interventions. Cholesteryl ester transfer protein (CETP) inhibitors have shown promise in improving lipid profiles, but their comparative effectiveness in reducing CVS outcomes remains unclear. This network meta-analysis and network meta-regression aimed to evaluate the comparative effectiveness of CETP inhibitors (Evacetrapib, Anacetrapib, Dalcetrapib, and Torcetrapib) on CVS outcomes, including CVS mortality, all-cause mortality, major adverse cardiovascular events, myocardial infarction, need for revascularization, and stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A Bayesian network meta-analysis was conducted, incorporating data from 10 randomized controlled trials with 84,134 patients diagnosed with cardiovascular disease or at high risk. We compared various CETP inhibitors for their effectiveness in reducing CVS events. Network meta-regression was used to assess the impact of covariates such as age, sex, and baseline lipid levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Evacetrapib ranked highest for CVS mortality (relative risk [RR]: 0.92, 95% credible interval [CrI]: 0.39\u20131.87; Surface Under the Cumulative Ranking Curve [SUCRA]: 71.91%) and Anacetrapib for major adverse cardiovascular events (RR: 0.40, 95% CrI: 0.07\u20131.06; SUCRA: 84.25%). Dalcetrapib showed favorable effects on all-cause mortality (RR: 0.72, 95% CrI: 0.16\u20131.42; SUCRA: 67.51%) and stroke (RR: 0.75, 95% CrI: 0.41\u20131.26; SUCRA: 83.03%). Anacetrapib had the highest rank in reducing myocardial infarction (RR: 0.83, 95% CrI: 0.46\u20131.15; SUCRA: 86.06%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This analysis suggests that Evacetrapib and Anacetrapib are the most effective CETP inhibitors for improving CVS outcomes, with Dalcetrapib showing beneficial effects in certain outcomes. Further studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048627","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:00:45Z","timestamp":1778896845000},"page":"e48627","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis and network meta-regression"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8995-1058","authenticated-orcid":false,"given":"Ibrahim","family":"Khalil","sequence":"first","affiliation":[{"name":"Dhaka Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Rafiqul","family":"Islam","sequence":"additional","affiliation":[{"name":"Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjida Amin","family":"Promi","sequence":"additional","affiliation":[{"name":"Chattogram Medical College, Chattogram, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam Das","family":"Joy","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Abu","family":"Sayed","sequence":"additional","affiliation":[{"name":"Chattogram Medical College, Chattogram, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durjoy","family":"Acharjee","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Saad","family":"Al-Shammari","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Baghdad, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Turzo","family":"Rahman","sequence":"additional","affiliation":[{"name":"Flushing Hospital Medical Center, Flushing, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakib","family":"Abrar","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Seen","family":"Bin Jamil","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika","family":"Taseen","sequence":"additional","affiliation":[{"name":"Gazi Medical College, Khulna, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suborna","family":"Biswas","sequence":"additional","affiliation":[{"name":"Shaheed Suhrawardy Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaya Khan","family":"Mifty","sequence":"additional","affiliation":[{"name":"Dhaka Medical College and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad Ghanim","family":"Al-Badri","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Baghdad, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avijit","family":"Debnath","sequence":"additional","affiliation":[{"name":"Jalalabad Ragib-Rabeya Medical College and Hospital, Sylhet, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Imran","family":"Hossain","sequence":"additional","affiliation":[{"name":"Manikganj Medical College, Manikganj, Bangladesh."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mst. Mahmuda","family":"Akter","sequence":"additional","affiliation":[{"name":"Manikganj Medical College, Manikganj, Bangladesh."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease.","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.","volume":"125","author":"Millar","year":"2015","journal-title":"J Clin Invest"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1194\/jlr.C085639","article-title":"In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.","volume":"59","author":"Tsimikas","year":"2018","journal-title":"J Lipid Res"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1253\/circj.CJ-16-1325","article-title":"Efficacy and safety of cholesteryl ester transfer protein inhibitor evacetrapib administered as monotherapy in Japanese patients with primary hypercholesterolemia.","volume":"81","author":"Teramoto","year":"2017","journal-title":"Circ J"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacl.2017.10.001","article-title":"Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.","volume":"12","author":"Arsenault","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MOL.0000000000000854","article-title":"Can we revive CETP-inhibitors for the prevention of cardiovascular disease?","volume":"33","author":"Nicholls","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","article-title":"Obicetrapib-the rebirth of CETP inhibitors?","volume":"26","author":"Chang","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacl.2014.10.005","article-title":"Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.","volume":"9","author":"Brinton","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"n47","DOI":"10.1016\/j.amjcard.2007.08.013","article-title":"Refocusing on use of cholesteryl ester transfer protein inhibitors.","volume":"100","author":"Kastelein","year":"2007","journal-title":"Am J Cardiol"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"517","DOI":"10.11124\/JBIES-24-00308","article-title":"Update to the PRISMA guidelines for network meta-analyses and scoping reviews and development of guidelines for rapid reviews: a scoping review protocol.","volume":"23","author":"Veroniki","year":"2025","journal-title":"JBI Evid Synth"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews.","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inference from iterative simulation using multiple sequences.","volume":"7","author":"Gelman","year":"1992","journal-title":"Statist Sci"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Syn Meth"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease.","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"R21-20260904","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","article-title":"Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of lipid level management using coronary ultrasound to assess reduction of atherosclerosis by CETP inhibition and HDL elevation).","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome.","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.","volume":"33","author":"L\u00fcscher","year":"2012","journal-title":"Eur Heart J"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of Lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial.","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease.","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/14656566.2024.2409324","article-title":"Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?","volume":"25","author":"Nicholls","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"R28-20260904","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/eurheartj\/ehp601","article-title":"Safety and tolerability of dalcetrapib (RO4607381\/JTT-705): results from a 48-week trial.","volume":"31","author":"Stein","year":"2010","journal-title":"Eur Heart J"},{"key":"R29-20260904","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"R30-20260904","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/CIRCGENETICS.116.001405","article-title":"Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes.","volume":"9","author":"Tardif","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"R31-20260904","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.amjcard.2013.08.041","article-title":"Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.","volume":"113","author":"Gotto","year":"2014","journal-title":"Am J Cardiol"},{"key":"R32-20260904","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacl.2015.11.014","article-title":"Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.","volume":"10","author":"Nicholls","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R33-20260904","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2017.04.008","article-title":"Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trial.","volume":"261","author":"Nicholls","year":"2017","journal-title":"Atherosclerosis"},{"key":"R34-20260904","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jacc.2006.06.067","article-title":"Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.","volume":"48","author":"Davidson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R35-20260904","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"R36-20260904","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2013.05.012","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.","volume":"230","author":"Teramoto","year":"2013","journal-title":"Atherosclerosis"},{"key":"R37-20260904","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"R38-20260904","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","article-title":"Obicetrapib: reversing the tide of CETP inhibitor disappointments.","volume":"26","author":"Kastelein","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"R39-20260904","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.5551\/jat.64828","article-title":"Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial.","volume":"31","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"R40-20260904","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"R41-20260904","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial.","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048627","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:00:45Z","timestamp":1788530445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":38,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048627","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2025-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}